Swiss drugmaker Novartis raises full-year guidance based on strong Q1 performance and projected growth for key products.
Novartis, a Swiss pharmaceutical company, increased its full-year guidance after reporting better-than-expected Q1 results. 2024 net sales are expected to grow by a high-single to low double-digit percentage, with adjusted operating income projected to grow by a low double-digit to mid-teens percentage. This upgrade is driven by strong performance from key products like Entresto, Cosentyx, and Kesimpta.
April 23, 2024
6 Articles